Palvella Therapeutics (NASDAQ:PVLA) Price Target Raised to $243.00

Palvella Therapeutics (NASDAQ:PVLA) had its price objective increased by Canaccord Genuity Group from $232.00 to $243.00 in a research note issued to investors on Monday morning,Benzinga reports. The firm currently has a buy rating on the stock.

PVLA has been the subject of several other research reports. Oppenheimer boosted their price target on shares of Palvella Therapeutics from $210.00 to $232.00 and gave the company an “outperform” rating in a report on Friday, November 6th. HC Wainwright assumed coverage on shares of Palvella Therapeutics in a research note on Friday, November 6th. They set a “strong-buy” rating on the stock. William Blair started coverage on shares of Palvella Therapeutics in a research note on Friday, October 16th. They issued an “outperform” rating for the company. Raymond James Financial set a $226.00 price objective on shares of Palvella Therapeutics in a research note on Friday, October 16th. Finally, Truist Financial set a $207.00 target price on Palvella Therapeutics in a research report on Wednesday, August 5th. Two research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $213.85.

Palvella Therapeutics Trading Down 2.8%

Shares of PVLA stock opened at $163.94 on Monday. Palvella Therapeutics has a twelve month low of $72.22 and a twelve month high of $179.95. The stock has a fifty day simple moving average of $143.61 and a two-hundred day simple moving average of $129.30.

Palvella Therapeutics (NASDAQ:PVLA) last announced its quarterly earnings results on Thursday, November 5th. The company reported ($1.70) EPS for the quarter, beating the consensus estimate of ($1.78) by $0.08. Equities research analysts predict that Palvella Therapeutics will post -6.26 earnings per share for the current fiscal year.

Insider Transactions at Palvella Therapeutics

In other news, COO Kathleen Goin sold 4,313 shares of the company’s stock in a transaction on Wednesday, October 21st. The shares were sold at an average price of $124.58, for a total value of $537,313.54. Following the sale, the chief operating officer directly owned 2,165 shares of the company’s stock, valued at $269,715.70. This represents a 66.58% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director George M. Jenkins sold 13,352 shares of the firm’s stock in a transaction that occurred on Monday, September 14th. The shares were sold at an average price of $151.96, for a total value of $2,028,969.92. Following the completion of the sale, the director directly owned 161,893 shares in the company, valued at approximately $24,601,260.28. The trade was a 7.62% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 61,056 shares of company stock worth $8,756,946 over the last three months. 17.20% of the stock is currently owned by insiders.

Institutional Trading of Palvella Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. Voya Investment Management LLC lifted its stake in Palvella Therapeutics by 2.8% in the third quarter. Voya Investment Management LLC now owns 5,878 shares of the company’s stock worth $811,000 after acquiring an additional 162 shares during the last quarter. KBC Group NV acquired a new position in shares of Palvella Therapeutics in the first quarter valued at approximately $28,000. Northwestern Mutual Wealth Management Co. purchased a new position in shares of Palvella Therapeutics during the 2nd quarter worth about $35,000. Sterling Capital Management LLC increased its position in Palvella Therapeutics by 907.7% during the 3rd quarter. Sterling Capital Management LLC now owns 393 shares of the company’s stock worth $54,000 after purchasing an additional 354 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its stake in Palvella Therapeutics by 31.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,783 shares of the company’s stock worth $248,000 after buying an additional 426 shares during the period. 40.11% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Palvella Therapeutics

Investors following PVLA have been watching these stories:

• Positive Sentiment: Canaccord Genuity Group reportedly expects PVLA shares to rise, providing a favorable analyst view. The report details, including any price target, were not included in the article summary. Article: Palvella Therapeutics Stock Price Expected to Rise
• Positive Sentiment: HC Wainwright maintained a “Strong-Buy” rating and projects Palvella could reach positive earnings by FY2030, forecasting $6.30 per share. This long-range outlook may offer optimism, though it is a forecast rather than a near-term catalyst. MarketBeat analyst estimates
• Neutral Sentiment: Palvella’s Q3 2026 earnings-call presentation was posted, but the provided article information does not describe its contents or disclose new results that would clarify the investment outlook. Article: Palvella Therapeutics Q3 2026 Earnings Call Presentation

Palvella Therapeutics Company Profile

Palvella Therapeutics is a clinical-stage biopharmaceutical company developing treatments for patients with rare and serious diseases, with a focus on conditions affecting the skin and related tissues. The company is based in Wayne, Pennsylvania. Its pipeline includes QTORIN-based topical drug candidates, which use the company’s platform to deliver medicines locally to affected tissue. Programs are being developed for conditions including microcystic lymphatic malformations and cutaneous venous malformations; these candidates are investigational and have not been established as approved treatments.